Article Details

Icosavax's $182M IPO haul is key for RSV, but eyes are on its Covid vaccine too

Retrieved on: 2021-08-01 15:45:00

Tags for this article:

Click the tags to see associated articles and topics

Icosavax's $182M IPO haul is key for RSV, but eyes are on its Covid vaccine too. View article details on hiswai:

Excerpt

... of a vaccine for the novel coronavirus. The biotech's $182 million IPO gives it the capital to move forward with clinical research on multiple programs.

Article found on: medcitynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up